|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recombinant baculoviruses that produce a putative non-structural protein 1 (NS1) of hepatitis C virus (HCV), predicted to be the second envelope glycoprotein, were constructed.
|
7686870 |
1993 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA encoding the first 126 amino acids of the HCV E1 envelope protein and the majority of the E1 signal sequence was analyzed in parallel with an 80-base-long segment of the 5' untranslated region (UTR).
|
18300072 |
2008 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis.
|
9658367 |
1998 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
MBL-HCV1 is a fully human monoclonal antibody recognizing a linear epitope of the HCV E2 envelope glycoprotein (amino acids 412-423).
|
24956119 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the structure of a broadly neutralizing antibody in complex with a conserved linear epitope from the HCV E2 envelope glycoprotein (residues 412 to 423; epitope I), we performed structure-based design of immunogens to induce antibody responses to this epitope.
|
28794021 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HCV polyprotein contains a hypervariable region (HVR1) located at the N terminus of the second envelope glycoprotein E2.
|
11356980 |
2001 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oral immunization of BALB/c mice with the attenuated Salmonella strain SL7207 carrying this plasmid efficiently induced HCV core and E2-specific cellular immune responses and antibodies.
|
21396407 |
2011 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used long-read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV infection to investigate the underlying viral population and evolutionary dynamics.
|
30602023 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.
|
8143975 |
1994 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sequence analysis of the structural protein region revealed extremely low sequence homology with all the four major HCV genotypes: 86-89% for the core protein and 56-69% for the envelope protein.
|
7602082 |
1995 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus.
|
1333186 |
1992 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variability of HCV was assessed by determining the nucleotide sequence corresponding to the hypervariable regions (HVR1 and HVR2) of the putative envelope protein (E2/NS1) in positive- and negative-stranded HCV RNA from the cancerous and surrounding non-cancerous liver tissue, peripheral blood mononuclear cells and serum of a patient with HCC.
|
8760588 |
1996 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The N-terminal end of the hepatitis C virus (HCV) envelope glycoprotein E2 contains a stretch of 27 amino acids that exhibit increased variability.
|
12526045 |
2003 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used a bioinformatics and functional approach to investigate whether E1/E2 envelope glycoprotein structure and function were associated with treatment failure in 92 patients infected with HCV genotype 1.
|
23335805 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that testing for anti-E2 may be useful for improving the performance of the current assays for anti-HCV screening and confirmation.
|
9123926 |
1996 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we constructed genetic vaccines based on novel recombinant adeno‑associated viral (rAAV) vectors (AAV2/8 or AAV2/rh32.33) that express the envelope glycoprotein E2 from the HCV genotype 1b.
|
30569131 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.
|
29951061 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we isolated 73 human mAbs recognizing five distinct antigenic regions on the virus envelope glycoprotein complex E1E2 from an HCV-immune phage-display antibody library by using an exhaustive-panning strategy.
|
22492964 |
2012 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection.
|
8382721 |
1993 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers.
|
29443378 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we rescued a recombinant PR8 influenza viral vector, called rgFLU-HCV<sub>CE1E2</sub>, carrying the core and envelope glycoprotein (C/E1/E2) epitopes of HCV inserted into the influenza nonstructural protein 1 gene.
|
28778831 |
2017 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that the E2/NS1 antibody tested exhibits no neutralizing activity in chronic HCV infection but may serve as a serological indicator of active virus replication.
|
8621173 |
1996 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic heterogeneity of HCV is greatest in the amino-terminal end of the second envelope protein (hypervariable region 1).
|
9305657 |
1997 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The hypervariable region 1 (HVR1) of the putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV) contains a sequence-specific immunological B-cell epitope that induces the production of antibodies restricted to the specific viral isolate, and anti-HVR1 antibodies are involved in the genetic drift of HVR1 driven by immunoselection (N. Kato, H. Sekiya, Y. Ootsuyama, T. Nakazawa, M. Hijikata, S. Ohkoshi, and K. Shimotohno, J. Virol.67:3923-3930, 1993).
|
7518526 |
1994 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.
|
22855498 |
2012 |